Skip to main content
SpringerLink
Log in

D-Cycloserine Augmentation of Cognitive-Behavioral Therapy: Directions for Pilot Research in Pediatric Obsessive-Compulsive Disorder

  • Original Paper
  • Published:
Child & Youth Care Forum Aims and scope Submit manuscript

Abstract

This paper discusses a recent translational success in combining behavioral psychotherapy with a novel medication, d-cycloserine (DCS), to augment cognitive-behavioral therapy (CBT) for anxiety disorders. The literature on behavioral theory of exposure-based therapies is provided, followed by a discussion of the role of DCS in enhancing extinction learning that is core to such therapies. As well, pragmatic issues such as dosing and timing are discussed. The manuscript is concluded with consideration of future directions in DCS augmentation in the form of a pilot trial investigating DCS augmentation of CBT in pediatric patients with obsessive-compulsive disorder.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abramowitz, J. S., Franklin, M. E., Zoellner, L. A., & DiBernardo, C. L. (2002). Treatment compliance and outcome of cognitive-behavioral therapy for obsessive-compulsive disorder. Behavior Modification, 26, 447–463.

    Article  PubMed  Google Scholar 

  • Abramowitz, J., Taylor, S., & McKay, D. (2005). Potentials and limitations of cognitive treatments for obsessive-compulsive disorder. Cognitive Behaviour Therapy, 34, 140–147.

    Article  PubMed  Google Scholar 

  • Baker, J. D., & Azorlosa, J. L. (1996). The NMDA antagonist MK-801 blocks the extinction of Pavlovian fear conditioning. Behavioral Neuroscience, 110, 618–620.

    Article  PubMed  Google Scholar 

  • Barrett, P. M., Farrell, L., Pina, A. A., Peris, T. S., & Piacentini, J. (2008). Evidence-based psychosocial treatments for child and adolescent obsessive-compulsive disorder. Journal of Clinical Child and Adolescent Psychology, 37, 131–155.

    Article  PubMed  Google Scholar 

  • Barrett, P., Healy-Farrell, L., & March, J. S. (2004). Cognitive behavioral family treatment of childhood obsessive-compulsive disorder: A controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 46–62.

    Article  PubMed  Google Scholar 

  • Beidel, D. C., & Turner, S. M. (1992). Scoring the Social Phobia and Anxiety Inventory. Journal of Psychopathology and Behavioral Assessment, 14, 377–379.

    Article  Google Scholar 

  • Benazon, N. R., Ager, J., & Rosenberg, D. R. (2002). Cognitive behavior therapy in treatment-naïve children and adolescents with obsessive-compulsive disorder: An open trial. Behaviour Research and Therapy, 40, 529–539.

    Article  PubMed  Google Scholar 

  • Bloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V., Bracken, M. B., & Leckman, J. F. (2006). A systematic review: Antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular Psychiatry, 11(7), 622–632.

    Article  PubMed  Google Scholar 

  • Boje, K. M., Wong, G., & Skolnick, P. (1993). Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures. Brain Research, 603, 207–214.

    Article  PubMed  Google Scholar 

  • Butterfield, D. A., & Pocernich, C. B. (2003). The glutamatergic system and Alzheimer’s disease: Therapeutic implications. CNS Drugs, 17, 641–652.

    Article  PubMed  Google Scholar 

  • Chambless, D. L., & Ollendick, T. H. (2001). Empirically supported psychological interventions: Controversies and evidence. Annual Review of Psychology, 52, 685–716.

    Article  PubMed  Google Scholar 

  • Correll, C. U., Manu, P., Olshanskiy, V., Napolitano, B., Kane, J. M., & Malhotra, A. K. (2009). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA, 302, 1765–1773.

    Article  PubMed  Google Scholar 

  • Davis, M. (2000). The role of the amygdala in conditioned and unconditioned fear and anxiety. In J. P. Aggleton (Ed.), The amygdale (Vol. 2, pp. 213–287). Oxford: Oxford University Press.

    Google Scholar 

  • Davis, M. (2002). Role of NMDA receptors and MAP kinase in the amygdala in extinction of fear. Clinical implications for exposure therapy. European Journal of Neuroscience, 16, 395–398.

    Article  PubMed  Google Scholar 

  • Davis, M., Walker, D. L., & Myers, K. M. (2003). Role of the amygdala in fear extinction measured with potentiated startle. Annals of the New York Academy of Science, 985, 218–232.

    Google Scholar 

  • de Haan, E., van Oppen, P., van Balkom, A. J., Spinhoven, P., Hoogduin, K. A., & van Dyck, R. (1997). Prediction of outcome and early vs. late improvement in OCD patients treated with cognitive behaviour therapy and pharmacotherapy. Acta Psychiatrica Scandinavica, 96, 354–361.

    Article  PubMed  Google Scholar 

  • Dougherty, D. D., Baer, L., Cosgrove, G. R., Cassem, E. H., Price, B. H., Nierenberg, A. A., et al. (2002). Prospective long-term follow-up of 44 patients who received cingulotomy for treatment-refractory obsessive-compulsive disorder. American Journal of Psychiatry, 159, 269–275.

    Article  PubMed  Google Scholar 

  • Douglass, H. M., Moffitt, T. E., Dar, R., McGee, R., & Silva, P. (1995). Obsessive-compulsive disorder in a birth cohort of 18-year-olds: Prevalence and predictors. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 1424–1431.

    Article  PubMed  Google Scholar 

  • Fakouhi, T. D., Jhee, S. S., Sramek, J. J., Benes, C., Schwartz, P., Hantsburger, G., et al. (1995). Evaluation of cycloserine in the treatment of Alzheiver’s disease. Journal of Geriatrics, Psychiatry, and Neurology, 8, 226–230.

    Google Scholar 

  • Falls, W. A., Miserendino, M. J., & Davis, M. (1992). Extinction of fear-potentiated startle: Blockade by infusion of an NMDA antagonist into the amygdala. Journal of Neuroscience, 12, 854–863.

    PubMed  Google Scholar 

  • Fanselow, M. S., Kim, J. J., Yipp, J., & De Oca, B. (1994). Differential effects of the N-methyl-D-aspartate antagonist DL-2-amino-5-phosphonovalerate on acquisition of fear of auditory and contextual cues. Behavioral Neurosicence, 108, 235–240.

    Article  Google Scholar 

  • Foa, E. B., & Kozak, M. J. (1986). Emotional processing of fear: Exposure to corrective information. Psychological Bulletin, 99, 20–35.

    Article  PubMed  Google Scholar 

  • Foa, E. B., & Kozak, M. J. (1996). Psychological treatments for obsessive-compulsive disorder. In M. R. Mavissakalian & R. F. Prein (Eds.), Long-term treatments for anxiety disorders (pp. 285–309). Washington, DC: American Psychiatric Press, Inc.

    Google Scholar 

  • Foa, E. B., Liebowitz, M. R., Kozak, M. J., Davies, S., Campeas, R., Franklin, M. E., et al. (2005). Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. American Journal of Psychiatry, 162, 151–161.

    Article  PubMed  Google Scholar 

  • Freeman, J. B., Garcia, A. M., Coyne, L., Ale, C., Przeworski, A., Himle, M., et al. (2008). Early childhood OCD: preliminary findings from a family-based cognitive-behavioral approach. Journal of the American Academy of Child and Adolescent Psychiatry, 47, 593–602.

    Article  PubMed  Google Scholar 

  • Geller, D. A., Biederman, J., Stewart, S. E., Mullin, B., Martin, A., Spencer, T., et al. (2003). Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive compulsive disorder. American Journal of Psychiatry, 160, 1919–1928.

    Article  PubMed  Google Scholar 

  • Goff, D. C., Cather, C., Gottlieb, J. D., Evins, A. E., Walsh, J., Raeke, L., et al. (2008). Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory study. Schizophrenia Research, 106, 320–327.

    Article  PubMed  Google Scholar 

  • Goodman, W. K., Murphy, T. K., & Storch, E. A. (2007). Risk of adverse behavioral effects with pediatric use of antidepressants. Psychopharmacology, 191, 87–96.

    Article  PubMed  Google Scholar 

  • Goodman, W. K., Price, L. H., Rasmussen, S. A., Mazure, C., Fleischmann, R. L., Hill, C. L., et al. (1989). The Yale-Brown Obsessive Compulsive Scale I. Development, use, and reliability. Archives of General Psychiatry, 46, 1006–1011.

    PubMed  Google Scholar 

  • Goodman, W. K., Ward, H., Kablinger, A., & Murphy, T. (1997). Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions. Journal of Clinical Psychiatry, 58(Suppl 5), 32–49.

    PubMed  Google Scholar 

  • Grados, M. A., & Riddle, M. A. (2001). Pharmacological treatment of childhood obsessive-compulsive disorder: From theory to practice. Journal of Clinical Child Psychology, 30, 67–79.

    Article  PubMed  Google Scholar 

  • Guastella, A. J., Richardson, R., Lovibond, P. F., Rapee, R. M., Gaston, J. E., Mitchell, P., et al. (2008). A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biological Psychiatry, 63, 544–549.

    Article  PubMed  Google Scholar 

  • Guy, W. (1976). Assessment Manual for Psychopharmacology, Revised (DHEW Publication ABM 76–366). Washington, DC: US Government Printing Office.

    Google Scholar 

  • Heresco-Levy, U., Ermilov, M., Shimoni, J., Shapira, B., Silipo, G., & Javitt, D. C. (2002). Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzipine, or risperidone in schizophrenia. American Journal of Psychiatry, 56, 21–27.

    Google Scholar 

  • Hofmann, S. G., Meuret, A. E., Smits, J. A., Simon, N. M., Pollack, M. H., Eisenmenger, K., et al. (2006). Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Archives of General Psychiatry, 63, 298–304.

    Article  PubMed  Google Scholar 

  • Jaurrieta, N., Jimenez-Murcia, S., Menchon, J. M., Del Pino Alonso, M., Segalas, C., Alvarez-Moya, E. M., et al. (2008). Individual versus group cognitive-behavioral treatment for obsessive-compulsive disorder: A controlled pilot study. Psychotherapy Research, 18, 604–614.

    Article  PubMed  Google Scholar 

  • Javitt, D., Zylberman, I., Zukin, S., Heresco-Levy, U., & Lindenmayer, J. P. (1994). Amelioration of negative symptoms in schizophrenia by glycine. American Journal of Psychiatry, 151, 1234–1236.

    PubMed  Google Scholar 

  • Jones, R. W., Wesnes, K. A., & Kirby, J. (1991). Effects of NMDA modulation in scopolamine dementia. Annals of the New York Academy of Science, 640, 241–244.

    Google Scholar 

  • Kalisch, R., Holt, B., Petrovic, P., De Martino, B., Klöppel, S., Büchel, C., et al. (2009). The NMDA agonist D-cycloserine facilitates fear memory consolidation in humans. Cerebral Cortex, 19, 187–196.

    Article  PubMed  Google Scholar 

  • Kordon, A., Kahl, K. G., Broocks, A., Voderholzer, U., Rasche-Rauchle, H., & Hohagen, F. (2005). Clinical outcome in patients with obsessive-compulsive disorder after discontinuation of SRI treatment: Results from a two-year follow-up. European Archives of Psychiatry and Clinical Neuroscience, 255, 48–50.

    Article  PubMed  Google Scholar 

  • Kraemer, H. C., Mintz, J., Noda, A., Tinklenberg, J., & Yesavage, J. A. (2006). Caution regarding the use of pilot studies to guide power calculations for study proposals. Archives of General Psychiatry, 63, 484–489.

    Article  PubMed  Google Scholar 

  • Kushner, M. G., Kim, S. W., Donahue, C., Thuras, P., Adson, D., Kotlyar, M., et al. (2007). D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biological Psychiatry, 62(8), 835–838.

    Article  PubMed  Google Scholar 

  • Lack, C. W., Storch, E. A., Keeley, M. L., Geffken, G. R., Ricketts, E. D., Murphy, T. K., et al. (2009). Quality of life in children and adolescents with obsessive-compulsive disorder: Base rates, parent-child agreement, and clinical correlates. Social Psychiatry and Psychiatric Epidemiology, 44, 935–942.

    Article  PubMed  Google Scholar 

  • Land, C., & Riccio, D. C. (1999). D-cycloserine: Effects on long-term retention of a conditioned response and on memory for contextual attributes. Neurobiology of Learning and Memory, 72, 158–168.

    Article  PubMed  Google Scholar 

  • Ledgerwood, L., Richardson, R., & Cranney, J. (2003). Effects of D-cycloserine on the extinction of conditioned freezing. Behavioral Neuroscience, 117, 341–349.

    Article  PubMed  Google Scholar 

  • Ledgerwood, L., Richardson, R., & Cranney, J. (2004). D-cycloserine and the facilitation of extinction of conditioned fear: Consequences for reinstatement. Behavioral Neuroscience, 118, 505–513.

    Article  PubMed  Google Scholar 

  • Ledgerwood, L., Richardson, R., & Cranney, J. (2005). D-cycloserine facilitates extinction of learned fear: Effects on reacquisition and generalized extinction. Biological Psychiatry, 57, 841–847.

    Article  PubMed  Google Scholar 

  • Lewin, A. B., & Piacentini, J. (2009). Obsessive-compulsive disorder in children. In B. J. Sadock, V. A. Sadock, & P. Ruiz (Eds.), Kaplan & Sadock’s comprehensive textbook of psychiatry (9th ed., pp. 3671–3678). Philadelphia: Lippincott, Williams & Wilkins.

    Google Scholar 

  • Lewin, A. B., Storch, E. A., Adkins, J., Murphy, T. K., & Geffken, G. R. (2005). Current directions in pediatric obsessive-compulsive disorder. Pediatric Annals, 34, 128–137.

    PubMed  Google Scholar 

  • Liebowitz, M. R. (1987). Social Phobia. Mod Probl Pharmacopsychiatry, 22, 141–173.

    PubMed  Google Scholar 

  • March, J. S., Franklin, M., Nelson, A., & Foa, E. (2001). Cognitive-behavioral psychotherapy for pediatric obsessive-compulsive disorder. Journal of Clinical Child Psychology, 30, 8–18.

    Article  PubMed  Google Scholar 

  • Maren, S., Aharanov, G., State, D., & Fanselow, M. S. (1996). N-methyl-D-aspartate receptors in the basolateral amygdala are required for both acquisition and expression of conditional fear in rats. Behavioral Neuroscience, 110, 1365–1374.

    Article  PubMed  Google Scholar 

  • Matsuoka, N., & Aigner, T. G. (1996). D-cycloserine, a partial agonist at the glycine site coupled to N-methyl-D-aspartate receptors, improves visual recognition memory in rhesus monkeys. The Journal of Pharmacology and Experimental Therapeutics, 278, 891–897.

    PubMed  Google Scholar 

  • Meyer, V. (1966). Modification of expectations in cases with obsessive rituals. Behavioral Research and Therapy, 4, 270–280.

    Google Scholar 

  • Millan, M. J. (2002). N-methyl-d-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: A critical review. Current Drug–Targets CNS and Neurological Disorders, 1, 191–213.

    Article  PubMed  Google Scholar 

  • Mower, O. H. (1939). A stimulus-response analysis of anxiety and its role as a reinforcing agent. Psychological Review, 46, 553–565.

    Article  Google Scholar 

  • Mowrer, O. A. (1960). Learning theory and behavior. New York: Wiley.

    Book  Google Scholar 

  • Murphy, T. K., Segarra, A., Storch, E. A., & Goodman, W. K. (2008). SSRI adverse events: How to monitor and manage. International Review of Psychiatry, 20, 203–208.

    Article  PubMed  Google Scholar 

  • Myers, K. M., & Davis, M. (2002). Behavioral and Neural Analysis of Extinction. Neuron, 36, 567–584.

    Article  PubMed  Google Scholar 

  • Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008). A meta-analysis of D-Cycloserine and the facilitation of extinction and exposure therapy for learned fear. Biological Psychiatry, 63, 1118–1126.

    Article  PubMed  Google Scholar 

  • Parnas, A. S., Weber, M., & Richardson, R. (2005). Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. Neurobiology of Learning and Memory, 84, 224–231.

    Article  Google Scholar 

  • Pediatric Obsessive-Compulsive Disorder Treatment Study (POTS) Team. (2004). Cognitive-behavioral therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: The Pediatric Obsessive-Compulsive Disorder Treatment Study (POTS) Randomized Controlled Trial. The Journal of the American Medical Association, 292, 1969–1976.

    Article  Google Scholar 

  • Piacentini, J., Bergman, R. L., Keller, M., & McCracken, J. (2003). Functional impairment in children and adolescents with obsessive-compulsive disorder. Journal of Child and Adolescent Psychopharmacology, 13S–1, S61–S69.

    Article  Google Scholar 

  • Posey, D. J., Kem, D. L., Swiezy, N. B., Sweeten, T. L., Wiegand, R. E., & McDougle, C. J. (2004). A pilot study of d-cycloserine in subjects with autistic disorder. American Journal of Psychiatry, 161, 2115–2117.

    Article  PubMed  Google Scholar 

  • Pussinen, R., Nieminen, S., Koivisto, E., Haapalinna, A., Riekkinen, P., Sr., & Sirvio, J. (1997). Enhancement of intermediate-term memory by an α1 agonist or a partial agonist at the glycine site of the NMDA receptor. Neurobiology, Learning, and Memory, 67, 69–74.

    Article  Google Scholar 

  • Quartermain, D., Mower, J., Rafferty, M. F., Herting, R. L., & Lanthorn, T. H. (1994). Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. European Journal of Pharmacology, 257, 7–12.

    Article  PubMed  Google Scholar 

  • Rachman, S. (1993). Obsessions, responsibility, and guilt. Behaviour Research and Therapy, 9, 225–238.

    Google Scholar 

  • Randolph, C., Roberts, J. W., Tierney, M. C., Bravi, D., Mouradian, M. M., & Chase, T. N. (1994). D-cycloserine treatment of Alzheimer’s disease. Alzheimers Disease and Associated Disorders, 8, 198–205.

    Google Scholar 

  • Ressler, K. J., & Nemeroff, C. B. (1999). Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biological Psychiatry, 46, 1219–1233.

    Article  PubMed  Google Scholar 

  • Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., et al. (2004). Cognitive enhancers as adjuncts to psychotherapy. Use of D-Cycloserine in phobic individuals to facilitate extinction of fear. Archives of General Psychiatry, 61, 1136–1142.

    Article  PubMed  Google Scholar 

  • Richardson, R., Ledgerwood, L., & Cranney, J. (2004). Facilitation of fear extinction by D-cycloserine: Theoretical and clinical implications. Learning & Memory, 11, 510–516.

    Article  Google Scholar 

  • Rothbaum, B. O., & Davis, M. (2003). Applying learning principles to the treatment of post-trauma reactions. Annals of the New York Academy of Science, 1008, 112–121.

    Article  Google Scholar 

  • Salkovskis, P. M. (1999). Understanding and treating obsessive-compulsive disorder. Behaviour Research and Therapy, 37, S29–S52.

    Article  PubMed  Google Scholar 

  • Storch, E. A., Merlo, L. J., Bengtson, M., Murphy, T. K., Lewis, M. H., Yang, M. C., et al. (2007a). D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. International Clinical Psychopharmacology, 22, 230–237.

    Article  PubMed  Google Scholar 

  • Storch, E. A., Merlo, L. J., Lehmkuhl, H., Geffken, G. R., Jacob, M., Ricketts, E., et al. (2007b). Cognitive-behavioral therapy for obsessive-compulsive disorder: A non-randomized comparison of intensive and weekly approaches. Journal of Anxiety Disorders, 22, 1146–1158.

    Article  PubMed  Google Scholar 

  • Taylor, S., McKay, D., & Abramowitz, J. (2005). Is Obsessive-Compulsive Disorder a disturbance of security motivation? Comment on Szechtman & Woody (2004). Psychological Review, 112, 650–656.

    Article  PubMed  Google Scholar 

  • Tsai, G. E., Falk, W. E., Gunther, J., & Coyle, J. T. (1999). Improved cognition in Alzheimer’s disease with short-term D-cycloserine treatment. American Journal of Psychiatry, 156, 467–469.

    PubMed  Google Scholar 

  • Tuominen, H. J., Tiihonen, J., & Wahlbeck, K. (2005). Glutametergic drugs for schizophrenia: A systematic review and meta-analysis. Schizophrenia Research, 72, 225–234.

    Article  PubMed  Google Scholar 

  • van Oppen, P., van Balkom, A. J., de Haan, E., & van Dyck, R. (2005). Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: A 5-year follow-up. Journal of Clinicall Psychiatry, 66, 1415–1422.

    Article  Google Scholar 

  • Walker, D. L., Ressler, K. J., Lu, K. T., & Davis, M. (2002). Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. Journal of Neuroscience, 22, 2343–2351.

    PubMed  Google Scholar 

  • Whittington, C. J., Kendall, T., Fonagy, P., Cottrell, D., Cotgrove, A., & Boddington, E. (2004). Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. Lancet, 363, 1341–1345.

    Article  PubMed  Google Scholar 

  • Wilhelm, S., Buhlmann, U., Tolin, D. F., Meunier, S. A., Pearlson, G. D., Reese, H. E., et al. (2008). D-cycloserine augmentation of behavior therapy for obsessive-compulsive disorder. American Journal of Psychiatry, 165, 335–341.

    Article  PubMed  Google Scholar 

  • Zhang, W. N., Bast, T., & Feldon, J. (2001). The ventral hippocampus and fear conditioning in rats: Different anterograde amnesias of fear after infusion of N-methyl-D-aspartate or its noncompetitive antagonist MK-801 into the ventral hippocampus. Behavioural Brain Research, 126, 159–174.

    Article  PubMed  Google Scholar 

  • Zohar, A. H. (1999). The epidemiology of obsessive-compulsive disorder in children and adolescents. Child and Adolescent Psychiatric Clinics of North America, 8, 445–460.

    PubMed  Google Scholar 

Download references

Acknowledgments

This paper were supported by grants from the National Institutes of Health (MH076775; L40 MH081950-02) and NARSAD to the first author.

Author information

Authors and Affiliations

  1. Department of Pediatrics, Rothman Center for Neuropsychiatry, University of South Florida College of Medicine, 800 6th Street South 4th Floor, St. Petersburg, FL, 33701, USA

    Eric A. Storch, Jeannette M. Reid, Adam B. Lewin & Tanya K. Murphy

  2. Department of Psychiatry, University of South Florida, Tampa, FL, USA

    Eric A. Storch & Tanya K. Murphy

  3. Department of Psychology, Fordham University, New York, NY, USA

    Dean McKay

  4. Massachusetts General Hospital, Boston, MA, USA

    Daniel A. Geller

  5. Mount Sinai Hospital, New York, NY, USA

    Wayne K. Goodman

Authors
  1. Eric A. Storch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dean McKay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeannette M. Reid
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniel A. Geller
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wayne K. Goodman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Adam B. Lewin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tanya K. Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric A. Storch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Storch, E.A., McKay, D., Reid, J.M. et al. D-Cycloserine Augmentation of Cognitive-Behavioral Therapy: Directions for Pilot Research in Pediatric Obsessive-Compulsive Disorder. Child Youth Care Forum 39, 101–112 (2010). https://doi.org/10.1007/s10566-010-9094-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10566-010-9094-6

Keywords

Search

Navigation